P1201: a real-world study of chidamide for patients with peripheral t-cell lymphoma in china

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Peripheral T-cell lymphoma (PTCL) is featured with a poor survival outcome. Targeting histone deacetylases (HDACs) has become a novel treatment option for PTCL. Chidamide is the first oral selective HDAC inhibitor. Aims: This observational study aimed to investigate the efficacy and safety of chidamide in patients with PTCL. Methods: From June 2015 to April 2022, 48 PTCL patients treated with chidamide were included in this study. Objective responses, progression-free survival (PFS), overall survival (OS), and safety were analyzed. Results: The median age was 59 years (range, 30 years to 85 years). Angioimmunoblastic T-cell lymphoma (AITL, 57.1%) was the main pathological subtype, followed by PTCL-not otherwise specified (PTCL-NOS, 14.3%), NK/T-cell lymphoma (NKTCL, 8.2%), anaplastic large cell lymphoma (ALCL, 6.1%) and other subtypes (14.3%). 77.6% of patients were previously untreated (38/49). 91.8% of patients had stage Ⅲ/Ⅳ disease (45/49). Thirty-three patients achieved objective responses with an overall response rate (ORR) of 67.4%, including 21 patients with complete response (CR). The 2-year PFS rate and 2-year OS rate were 51.5% and 68.5%, respectively. Among the 27 previously untreated patients who received chidamide combined with chemotherapy, the ORR of all various PTCL subtypes, AITL and PTCL-NOS were 85.2%, 68.8% and 75.0%, respectively. The most common adverse events (AEs) were hematological toxicities. 24.5% of patients reduced the dosage or stoped using chidamide due to AEs (12/49). No treatment-related death occurred. Summary/Conclusion: The favorable efficacy and safety profiles indicate that chidamide would be a new therapeutic option in patients with PTCL. Keywords: Safety, Peripheral T-cell lymphoma, Inhibitor, Clinical outcome